Compare GoPro Inc (GPRO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Moderna, Inc. — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 323× GoPro Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Moderna, Inc. for 59 Days on average.
| GPRO | MRNA | |
|---|---|---|
Market Cap | $243.50M | $78.65B |
Volume | 11,527,160 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $2.31 | $225.00 |
52-Week Low | $0.58 | $22.36 |
Typical Hold Time | 45 Days | 59 Days |
Enterprise Value | $302.28M | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 3.28% today, amid volatile trading following a recent merger announcement with Starman Optical. The company faces fundamental challenges with negative net income margins (-28.52%) and declining revenue, though valuation ratios appear low with P/E of 4.56 and P/S of 0.34. Technical indicators show a bullish overall signal with RSI at oversold levels, while analyst sentiment remains mixed with only 21% recommending Buy.
The proposed $285 million merger offers potential upside from current levels, but significant execution risks and ongoing cash burn (-$53M net cash flow) create substantial uncertainty. Investors face binary outcomes between merger completion benefits and continued operational struggles in a competitive camera market.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
